

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Parent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/781,464	02/17/2004	Srinivasa Madhyastha	14233.15USU1	1780	
23552	7590 09/11/2006		EXAM	EXAMINER	
MERCHANT & GOULD PC			KAM, CHIH MIN		
P.O. BOX 2903 MINNEAPOLIS, MN 55402-0903			ART UNIT	PAPER NUMBER	
			1656	· ·	
			DATE MAILED: 09/11/200	DATE MAILED: 09/11/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
Office Action Summary		10/781,464	MADHYASTHA, SRINIVASA		
		Examiner	Art Unit		
		Chih-Min Kam	1656		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
WHIC - Exter after - If NO - Failu Any (ORTENED STATUTORY PERIOD FOR REPL'CHEVER IS LONGER, FROM THE MAILING Designs of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. Period for reply is specified above, the maximum statutory period vere to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	. the mailing date of this communication. (35 U.S.C. § 133).		
Status			•		
2a)	Responsive to communication(s) filed on <u>21 A</u> This action is FINAL . 2b) This Since this application is in condition for allowar closed in accordance with the practice under E	s action is non-final. nce except for formal matters, pro			
Dispositi	on of Claims				
4) Claim(s) 42-46 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 42-46 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.					
Applicati	on Papers				
10)⊠	The specification is objected to by the Examine The drawing(s) filed on <u>09 September 2005</u> is/a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	are: a) \square accepted or b) \square object drawing(s) be held in abeyance. See this required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).		
Priority u	ınder 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary (Paper No(s)/Mail Da			
3) 🔲 Inforn	nation Disclosure Statement(s) (PTO/SB/08) No(s)/Mail Date	5) Notice of Informal Pa			

DETAILED ACTION

1. The final rejection of previous Office Action dated June 21, 2006 is withdrawn due to a ground rejection.

Status of the Claims

2. Claims 42-46 are pending.

Applicant's amendment filed August 21, 2006 is acknowledged, and applicants' response has been fully considered. Claim 42 has been amended, and claims 12-14 and 35-41 have been cancelled. Therefore, claims 42-46 are examined.

3. The status of claims 43-46 are indicated as new claims, which is not right since these claims are previously presented. Appropriate correction is required.

Claim Objections

4. Claim 43 is objected to because of the use of the term "a voice prosthetic". Use of "a voice prosthetic device". The claim is also objected to because it recites "tubing" twice.

Withdrawn-Claim Rejections - 35 U.S.C. § 103

- 3. The previous rejection of claims 12-14 under 35 U.S.C. § 103(a) as being unpatentable over Charter *et al.* (US 2002/0001582) taken with Johansen (WO 96/06532), is withdrawn in view of applicant's cancellation of the claim, and applicant's response at page 4 in the amendment filed August 21, 2006.
- 4. The previous rejection of claims 35-41 under 35 U.S.C. § 103(a) as being unpatentable over Willcox *et al.* (CA 2, 284,364) taken with Tomita *et al.* (EP 629347), is withdrawn in view of applicant's cancellation of the claim, and applicant's response at page 4 in the amendment filed August 21, 2006.

Application/Control Number: 10/781,464

Art Unit: 1656

New Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. Claims 42-46 are rejected under 35 U.S.C. 103(a) as being unpatentable over Willcox et al. (CA 2, 284,364, published April 2, 2002) taken with Tomita et al. (EP 629347, published at December 21, 1994) and Johansen (WO 96/06532).

Willcox *et al.* disclose an antimicrobial agent such as lactoferrin is used to coat a surface of a biomedical device, where the biomedical device is meant any device designed to be used in or on either or both human tissue or fluid, e.g., stents, implants, catheters and ophthalmic lenses (page 2; claims 37-41), and wherein the surface on the biomedical device is a polymer of ethylene or propylene, polyurethanes, polyesters and mixtures thereof, or silicones containing hydrogels (page 4, lines 15-29). However, Willcox *et al.* do not teach the use of ovotransferrin, protamine sulfate and EDTA, or ovotransferrin and protamine sulfate in the coatings.

Tomita *et al.* disclose an antimicrobial agent comprising lactoferrin hydrolysates, one or more antimicrobial peptides from lactoferrin; and one of more compounds selected from the group consisting of metal-chelating protein (e.g., lactoferrin, transferrin, conalbumin; page 5, lines 36-38), tocopheol, EDTA or a salt thereof, or others (page 4, lines 11-19). The reference also teaches the antimicrobial agent can be used for treatment of any products or materials thereof, e.g., dentrifrices, diapers or others (page 6, lines 23-42).

Page 4

Application/Control Number: 10/781,464

Art Unit: 1656

Johansen discloses a bacteriocidal or fungicidal composition comprising a basic protein in combination with a cell-wall degrading enzyme or an oxidoreductase, where either protamine or protamine sulfate can be used as the basic protein (page 3, line 11-page 4, line 15).

At the time of invention was made, it would have been obvious that one of ordinary skill in the art is motivated to combine the three references to use the antimicrobial agent containing lactoferrin, lactoferrin peptides, conalbumin and EDTA as taught by Tomita et al. and the antimicrobial composition comprising protamine sulfate as taught by Johansen in preparing an antimicrobial agent to coat a surface of a biomedical device such as stents, implants, catheters and ophthalmic lenses as taught by Willcox et al. (claims 42-43) because the antimicrobial agent taught by Tomita et al. contains additional antimicrobial compounds such as EDTA and lactoferrin peptides, conalbumin in addition to lactoferrin; the antimicrobial composition taught by Johansen contains protamine sulfate; and it is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose (See MPEP 2144.06 and Ex parte Quadranti, 25 USPQ2d 1071 (Bd. Pat. App. & Inter. 1992)). Since and the medical devices recited in the claims are well-known medical devices (claims 44-46), thus, the combined references result in the claimed invention and was, as a whole, prima facie obvious at the time the claimed invention was made.

Application/Control Number: 10/781,464

Art Unit: 1656

Conclusion

6. No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr can be reached at 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications
may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Chih-Min Kam, Ph. D.

Primary Patent Examiner

Primary

CHIH-MIN RAM WIENT EXAMINER

Page 5

CMK

September 6, 2006